THURSDAY, Aug. 14 (HealthDay News) -- Preliminary results from an early trial of a new immunotherapy suggests doctors may soon have another weapon for the treatment of non-Hodgkin lymphoma.

A team of German scientists and clinicians led by Patrick Baeuerle, chief scientific officer at Micromet AG, a Munich-based biopharmaceutical company, demonstrated partial or complete tumor regression in 11 of 38 human patients given low doses of blinatumomab, a protein that tethers tumor-killing T-cells to cancerous B cells.

By Serena Gordon
EmpowHer's HealthDay Reporter

TUESDAY, March 4 (HealthDay News) -- Oral allergy immunotherapy -- in the form of drops or tablets -- is effective at reducing asthma symptoms and the need for asthma medications in children who have what's known as allergic asthma, a new study finds.

The findings bolster hopes that these oral medications might someday replace injections, never a hit with kids.